Single High-Dose Psilocybin Treatment Shows Temporary Cognitive Improvement in 80-Year-Old Alzheimer's Patient
An elderly Japanese-American woman with advanced Alzheimer's disease showed striking but temporary improvements in speech, memory, mobility, and continence after receiving two supervised doses of psilocybin-containing mushrooms, according to a case report published in Frontiers in Neuroscience. The Brazilian study authors noted the woman had experienced severe cognitive and functional decline for roughly five years before the sessions. While the findings are notable, researchers and outside experts caution that a single uncontrolled case cannot establish that psilocybin caused the improvements or that the approach is safe.
A case report published in Frontiers in Neuroscience describes an 80-something Japanese-American woman with approximately a decade of Alzheimer's disease progression who received two supervised sessions of psilocybin-containing mushrooms — a 5-gram dose followed by a 3-gram dose one month later. Prior to treatment, she communicated mainly in single words, required full caregiver assistance, experienced urinary incontinence, and had severely limited mobility. Roughly 19 hours after the first dose, she spontaneously initiated hours-long autobiographical conversation; in the days and weeks that followed, caregivers reported she walked independently, dressed herself, recognized family members, and regained continence. After the second session, she showed further improvements in expressiveness, humor, and agility. The study's authors and outside experts stress significant limitations: the diagnosis was not confirmed with modern biomarkers, there was no control group or standardized cognitive testing, observations relied heavily on caregiver reports, and the improvements may reflect natural fluctuation rather than a drug effect. Researchers hypothesize psilocybin may have temporarily altered communication between surviving brain networks — a mechanism consistent with its known action on serotonin receptors and animal studies suggesting it promotes neuroplasticity — but no brain imaging was performed to test this. Experts uniformly call for controlled clinical trials before any conclusions about psilocybin's safety or efficacy in Alzheimer's patients can be drawn.
What's missing
The report does not include longer-term follow-up beyond approximately one month after the second session, leaving it unknown whether any improvements persisted, faded, or were followed by accelerated decline. Additionally, the exact psilocybin dose is uncertain because mushroom potency varies, a pharmacological detail relevant to reproducibility.
How coverage differed
Fox News emphasized skepticism from named medical commentators, including a Fox News analyst who called the study's significance 'dubious,' and highlighted psilocybin's federal illegal status alongside state-level legalization trends. The Conversation and Medical Xpress framed the case more neutrally as a scientifically intriguing but preliminary finding, with The Conversation drawing a literary parallel to Oliver Sacks's 'Awakenings' to contextualize the phenomenon without sensationalizing it.
What different sources said
- Medical XpressCenter
Single high dose of psilocybin temporarily restores lost abilities in an 80-year-old Alzheimer's patient
- Fox NewsRight
Woman with advanced Alzheimer's regained speech and memories after taking magic mushrooms
- The ConversationCenter
Magic mushrooms and Alzheimer’s: what one remarkable case can tell us
Related
Chicago Woman's Five-Year Symptom Journey Leads to Rare Brain Tumor Diagnosis
Melony Aponte, 26, was diagnosed with a 4.5-centimeter acoustic neuroma after five years of symptoms she attributed to stress, COVID-19, and aging. The rare, noncancerous tumor—affecting roughly one in 100,000 people—had grown large enough to compress her hearing and balance nerve before it was identified via MRI in March 2025. Her case highlights how acoustic neuroma symptoms can mimic common conditions, potentially delaying diagnosis for years.
Study Finds Aging Shifts Walking Strategy Toward Stability at the Cost of Efficiency
A new study from Flinders University and the University of Canberra found that as people age, their bodies adopt a 'safety-first' walking pattern that prioritizes balance over efficient movement. Researchers analyzed gait data from 107 healthy adults aged 26 to 86, identifying increased ankle muscle co-contraction and reduced push-off power as key age-related changes. The findings suggest that fall prevention programs should target balance and coordination, not just muscle strength.
Tick Populations Surge in Urban Areas Across Northeast
Experts across the northeastern United States and Canada are warning of an unusually early and widespread tick season, with disease-carrying ticks increasingly found in urban parks and green spaces. Lyme disease cases in Canada reached a record 7,105 in 2025, up from 5,809 the previous year, while U.S. cities including Philadelphia, Pittsburgh, Washington D.C., and New York are reporting rising tick activity. The expansion poses a public health challenge because urban residents are less likely to take tick-bite precautions than those in rural areas.